Unraveling the therapeutic benefit of sequenced chemo-immunotherapy.

Combination immune-checkpoint inhibition with chemotherapy is a clinical standard yet concurrent administration may limit the full benefit of immunotherapy by blunting the proliferation and differentiation of CD8 T cells. Identifying patients where sequential chemo-immunotherapy or immunotherapy alone is feasible should be a priority to optimize long-term outcomes.